Halozyme's pancreatic cancer drug succeeds in mid-stage trial

(Reuters) - Halozyme Therapeutics Inc said its lead drug to treat a late form of pancreated cancer met the main goal in a mid-stage study, sending its shares soaring in premarket trading.